Duration of Targeted Therapy for Metastatic Renal Cell Carcinoma: A Review of Current Practices

Publisher： Karger

E-ISSN： 1423-0232|82|4|189-196

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.4, 2012-03, pp. : 189-196

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted therapy after metastasectomy

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 2, 2015-02 ,pp. : 153-157

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeted Therapy in the Treatment of Metastatic Renal Cell Cancer

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 122-131

Karger

Access to resources Recommend Favorite

Performing Cytoreductive Nephrectomy following Targeted Sunitinib Therapy for Metastatic Renal Cell Carcinoma: A Surgical Perspective

By  

Urologia Internationalis, Vol. 89, Iss. 1, 2012-05 ,pp. : 83-88

Karger

Access to resources Recommend Favorite

Delayed Cytoreductive Nephrectomy Following Three Years of Targeted Therapy for Metastatic Renal Cell Carcinoma

By  

Current Urology, Vol. 9, Iss. 4, 2016-12 ,pp. : 202-208

Karger

Access to resources Recommend Favorite

Retrospective Analysis of Fifth-Line Targeted Therapy Efficacy in Patients with Metastatic Renal Cell Carcinoma

By  

Urologia Internationalis, Vol. 98, Iss. 2, 2016-03 ,pp. : 184-190

Karger

Access to resources Recommend Favorite